Targets › PRKC
1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on PRKC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IDEAYA Biosciences | Darovasertib Protein Kinase C (PKC) inhibitor | PRKC | Phase 3 | Uveal Melanoma | Apr 2027 |
Uveal Melanoma (3)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.